-
Uncategorized2 months agoPsychedelics get a boost from the White House
President Trump recently signed an executive order which aims to increase access to psychedelic drug treatments. He was joined at the signing by podcaster Joe Rogan,...
-
Uncategorized2 months ago
Opinion: Prasad’s FDA exit good for rare diseases but new CBER head must repair eroded trust
Opinion: Prasad’s FDA exit good for rare diseases but new CBER head must repair eroded trust
-
Uncategorized2 months agoA CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
How did a biotech company that almost ran out of money three times get acquired for over $3 billion? Will the M&A streak continue? And why...
-
Uncategorized2 months agoEnabling In Vivo Lentiviral Therapies: Manufacturing Strategies to Improve Purity, Scalability, and Clinical Readiness
Lentiviral vectors are gaining momentum not just as ex vivo tools but as potential in vivo therapeutic platforms. But with that shift comes a number of...
-
Uncategorized2 months agoSTAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
WASHINGTON — President Trump heralded a drug pricing agreement with Regeneron on Thursday, closing the last of 17 deals initially sought by the White House last...
-
Uncategorized2 months agoFDA approves Regeneron’s hearing loss gene therapy
Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and...
-
Uncategorized2 months ago
CRISPR Base Editing Repairs Hard-to-Treat Cystic Fibrosis Mutation in Cell Models
Affecting an estimated 100,000 people globally, cystic fibrosis (CF) cases stem from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. In the past several...
-
Uncategorized2 months ago
FDA approves Regeneron’s hearing loss gene therapy Otarmeni
Regeneron has won the first ever FDA approval for a gene therapy to treat a rare type of inherited hearing loss, and the company plans to...
-
Uncategorized2 months ago
Substance use disorder biotech Tempero to close after earlier ‘serious’ safety event
Tempero Bio, a drug developer that had big ambitions to shake up the treatment of substance use disorders, is winding down operations, Endpoints News has learned....
-
Uncategorized2 months agoHeart’s beat may help it beat cancer, mouse research suggests
Heart disease and cancer are the leading causes of death in the United States, but it is rare that cancer makes its way to the heart. ...
Hantavirus One-Shot mRNA Vaccine Fully Protects in Syrian Hamster Model
SonoThera Raises $125M to Develop Ultrasound-Mediated Genetic Medicines
